Translate

Showing posts with label GI cards. Show all posts
Showing posts with label GI cards. Show all posts

Monday, 21 May 2012

Metronidazole


Class: Nitroimidazole derivative
Mech.: Inhib. DNA synth, degrades DNA, e- acceptor for reduced substrates.


Absorption: Complete, quick oral absorption.
Dist.: Well distrib to all tissues and fluids (including CSF)
Metab.: Hepatic metab.
Excretion, t_:
Toxicity/S.E.s: GI, metallic taste, neurotox (vertigo), disulfiram-like effect w/alcohol, neutropenia. Not for first trimester preg (mutagenic). Not for patients w/active CNS disease or hist. of blood dyscrasias.

Utility: IV treatment of anaerobic infects. Oral for amebiasis, giardiasis, and genital infects of Trichomonas vaginalis. H. pylori (PUD).
Special Features: Antiparasitic and antibacterial activity. All anaerobic cocci and anaerobic gram- bacilli, including Bacterioides. Trichomoniasis, amebiasis, giardiasis.

Cimetidine


Class: H2 Receptor Antagonist
Mech.: Competitive inhib. of the histamine H2 receptor, but not of the H1 receptor → inhib. of fasting and stim. acid secretion. No disruption of circadian rhythm of acid secretion. Inhib. of 80-90% of gastrin and
vagal-stim. acid secretion.

Absorption: Oral → rapid, good absorption. Single nighttime dose.
Dist.:
Metab.: Partial hepatic metab.
Excretion, t_: Excreted intact in urine. 1.5-3 hr.
Toxicity/S.E.s: Uncommon. Diarrhea, headaches, myalgias, skin rashes. Large doses over prolonged periods assoc. w/impotence & gynecomastia. Inhib. cyt. P-450 → dose adjustment with phenytoin, warfarin, & theophylline. Occasional cardiac arrhythmias.
Utility: PUD, Zollinger-Ellison synd., acute stress ulcers, GERD

Special Features: Potency—famotidine > ranitidine/nizatidine > cimetidine.
Tachyphylaxis—50% less effective after 6 months. Rebound hypersecretion 2° to receptor upregulation and inhib. of ATPase recycling.

Omeprazole


Class: Proton Pump Inhibitor
Mech.: Irreversible inhib. of H+/K+ ATPase → > 95% inhib. of acid secretion.

Absorption: Oral → 30-40% bioavail. Peak plasma levels at 0.5-3.5 hr. Give prior to meals, preferably in the morning. Additional dose, if necessary, should be given later in the day.
Dist.:
Metab.:
Excretion, t_: 0.5-1 hr.
Toxicity/S.E.s: Rare headache, diarrhea, rash. Inhib. of cyt. P-450 requires altered doses of warfarin, phenytoin, diazepam, and cyclosporin. Inhib. of vitamin. B12 absorption.

Utility: PUD, erosive esophagitis, Zollinger-Ellison synd., GERD.
Special Features: Mismatch between pharmacokinetics & pharmacodynamics. Short t_, but actions last > 24 hr (irreversible binding). Acid inhib. → ↑ gastrin

Ranitidine


Class: H2 Receptor Antagonist
Mech.: Competitive inhib. of the histamine H2 receptor, but not of the H1 receptor → inhib. of fasting and stim. acid secretion. No disruption of circadian rhythm of acid secretion. Inhib. of 80-90% of gastrin and
vagal-stim. acid secretion.


Absorption: Oral → rapid, good absorption. Single nighttime dose.
Dist.:
Metab.: Partial hepatic metab.
Excretion, t_: Excreted intact in urine. 1.5-3 hr.
Toxicity/S.E.s: Uncommon. Diarrhea, headaches, myalgias, skin rashes. Inhib. cyt. P-450 (less than cimetidine) → dose adjustment with phenytoin, warfarin, & theophylline. Occasional cardiac arrhythmias.


Utility: PUD, Zollinger-Ellison synd., acute stress ulcers, GERD
Special Features: Potency—famotidine > ranitidine/nizatidine > cimetidine.
Tachyphylaxis—50% less effective after 6 months. Rebound
hypersecretion 2° to receptor upregulation and inhib. of ATPase recycling.